ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) announced a quarterly dividend on Tuesday, June 24th, NASDAQ Dividends reports. Investors of record on Wednesday, June 25th will be given a dividend of 0.1706 per share by the exchange traded fund on Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 1.49%. The ex-dividend date is Wednesday, June 25th. This is a 30.3% increase from ProShares Ultra Nasdaq Biotechnology's previous quarterly dividend of $0.13.
ProShares Ultra Nasdaq Biotechnology Stock Down 1.6%
BIB traded down $0.77 during trading on Wednesday, hitting $45.94. The company's stock had a trading volume of 5,310 shares, compared to its average volume of 11,379. The stock has a market capitalization of $50.53 million, a price-to-earnings ratio of 20.68 and a beta of 1.63. The firm's 50 day moving average price is $44.34 and its two-hundred day moving average price is $49.23. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $33.78 and a 12 month high of $69.56.
ProShares Ultra Nasdaq Biotechnology Company Profile
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
